Contemporary outcomes and disease burden of high-grade T1 bladder cancer
Contemporary five-year recurrence and progression rates for HGT1 bladder cancer remain high at 53% and 28%, respectively. The disease burden is substantial, with a median time between recurrences of seven months. These results can inform patient counseling, management, and clinical trial design.
Authors
- Aria F. Olumi (ORCID: https://orcid.org/0000-0001-5356-2558)
- Boris Gershman (ORCID: https://orcid.org/0000-0001-5191-7255)
- Aaron Fleishman (ORCID: https://orcid.org/0000-0001-7338-8235)
- Ruslan Korets (ORCID: https://orcid.org/0000-0003-0388-4545)
- Agustín Pérez-Londoño (ORCID: https://orcid.org/0000-0002-1117-1679)
- Heidi J. Rayala (ORCID: https://orcid.org/0000-0003-4500-0939)
- Joaquim Bellmunt (ORCID: https://orcid.org/0000-0003-2328-3421)
- Andrew Wagner (ORCID: https://orcid.org/0000-0002-9525-3208)
- Sumedh Kaul (ORCID: https://orcid.org/0000-0001-5707-1561)
- Peter Chang
Institutions
- Beth Israel Deaconess Medical Center (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- Canadian Urological Association Journal
- Published
- 2025-11-25
- DOI
- https://doi.org/10.5489/cuaj.9329
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00